MannKind Wins FDA Approval for Furoscix ReadyFlow, Secures $50M PIPE

MannKind NASDAQ: MNKD said the U.S. Food and Drug Administration approved Furoscix ReadyFlow, an auto-injector designed to deliver an 80-milligram dose of subcutaneous furosemide in five to 10 seconds for the management of fluid overload. Chief Executive Officer Michael Castagna said the approval was the company’s third FDA action in 2026, following an Afrezza conversion-dose update in the first quarter and a pediatric approval in the second quarter. MannKind expects to launch Furoscix ReadyFlow during the third quarter. The company also announced a $50 million private investment in public equity, or PIPE, financing led by Frazier Life Sciences. Castagna said the financing will support a $45 million contingent value right payment triggered by the ReadyFlow approval. Chief Medical Officer Dr. Ajay Ahuja said the FDA approval was supported by a prospective, randomized crossover pharmacokinetic and pharmacodynamic study involving 21 healthy adult volunteers. Each participant received both ReadyFlow and intravenous furosemide, with a three-day washout period between treatments. In the ReadyFlow arm, participants received 80 milligrams of furosemide subcutaneously through the auto-injector. The IV comparator consisted of two 40-milligram furosemide boluses administered two hours apart, according to the FDA label. Ahuja said ReadyFlow achieved 107% bioavailability relative to IV furosemide, within the 80% to 125% range used to establish bioequivalence. While the subcutaneous injection produced a lower and more gradual concentration peak than IV administration, overall drug exposure measured by area under the curve was equivalent, he said. The study also found that ReadyFlow generated urine output comparable with IV furosemide at six, eight and 12 hours, with similar urinary sodium and potassium excretion. Ahuja said injection-site adverse events were generally mild and local, while systemic adverse events were consistent with the known safety profile of oral and IV furosemide. No participants discontinued treatment because of an adverse event. Commercial Focus on Outpatient and Hospital Settings Castagna said MannKind views ReadyFlow as a potential tool for addressing fluid overload before hospitalization, supporting earlier discharge for appropriate patients and managing patients after discharge. He said the company estimates roughly 1 million addressable fluid-overload events occur annually in the U.S. Furosemide has historically been administered orally or intravenously in a hospital setting, according to Castagna. The prior Furoscix on-body infuser delivers treatment over five hours, while ReadyFlow is intended to provide a full dose through an auto-injector in seconds. MannKind refers to the emerging category as non-oral diuretics, or NODs. The company plans to train and deploy its sales force over the coming weeks and launch an integrated marketing campaign aimed at healthcare professionals a...